Biogen's SWOT analysis: neurology giant faces pipeline hurdles, stock outlook mixed
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
Breaking Down Biogen: 18 Analysts Share Their Views
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
Biogen (BIIB) Gets a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Biogen Beats Humana's RICO Suit Over MS Drug Scheme on Appeal
Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...
pharmaphorum7d
NICE backs Biogen's Vumerity for multiple sclerosis
Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the drug for ...
Seeking Alpha26d
Biogen Holds On, But Growth Slips Through Its Fingers
Biogen's stock underperformed in 2024 due to poor sales of Leqembi and declining multiple sclerosis revenues, despite efforts to diversify its pipeline. Leqembi's market struggles continue ...
Biogen (BIIB) Gets a Buy from RBC Capital
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1)
Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...
Nasdaq13d
Biogen's Quarterly Earnings Preview: What You Need to Know
Biogen has underperformed over the past year due to slow sales of its Alzheimer's drug, Leqembi, setbacks in its drug pipeline, declining multiple sclerosis revenues, high operational costs ...